MaxCyte (MXCT) Financials

MaxCyte logo
$1.18 -0.01 (-0.42%)
Closing price 03:59 PM Eastern
Extended Trading
$1.18 0.00 (0.00%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for MaxCyte

Annual Income Statements for MaxCyte

This table shows MaxCyte's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-13 -12 -19 -24 -38 -41 -45
Consolidated Net Income / (Loss)
-13 -12 -19 -24 -38 -41 -45
Net Income / (Loss) Continuing Operations
-13 -12 -19 -24 -38 -41 -45
Total Pre-Tax Income
-13 -12 -19 -24 -38 -41 -45
Total Operating Income
-12 -11 -18 -27 -48 -51 -52
Total Gross Profit
19 23 30 39 37 32 27
Total Revenue
22 26 34 44 41 39 33
Operating Revenue
22 26 34 44 41 39 33
Total Cost of Revenue
2.50 2.77 3.65 5.10 4.74 7.10 6.22
Operating Cost of Revenue
2.50 2.77 3.65 5.10 4.74 7.10 6.22
Total Operating Expenses
32 34 48 67 85 83 79
Selling, General & Admin Expense
5.56 7.37 19 26 30 30 28
Marketing Expense
7.85 8.33 13 19 27 27 19
Research & Development Expense
18 18 15 20 24 22 21
Depreciation Expense
0.54 1.03 1.35 2.53 3.99 4.14 4.23
Other Operating Expenses / (Income)
- - - - - 0.00 3.06
Impairment Charge
- - - - - 0.00 3.55
Total Other Income / (Expense), net
-0.48 -0.76 -0.89 3.79 10 10 7.27
Interest & Investment Income
0.21 0.07 0.15 3.92 10 10 7.27
Income Tax Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Basic Earnings per Share
($0.23) ($0.17) ($0.21) ($0.23) ($0.37) ($0.39) ($0.42)
Weighted Average Basic Shares Outstanding
56.40M 69.46M 90.62M 101.70M 103.27M 104.85M 106.43M
Diluted Earnings per Share
($0.23) ($0.17) ($0.21) ($0.23) ($0.37) ($0.39) ($0.42)
Weighted Average Diluted Shares Outstanding
56.40M 69.46M 90.62M 101.70M 103.27M 104.85M 106.43M
Weighted Average Basic & Diluted Shares Outstanding
- - 101.51M 102.90M 104.13M 106.03M 106.86M

Quarterly Income Statements for MaxCyte

This table shows MaxCyte's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-9.53 -9.38 -12 -11 -10 -12 -12 -9.60 -4.75 -8.87 -4.76
Consolidated Net Income / (Loss)
-9.53 -9.38 -12 -11 -10 -12 -12 -9.60 -4.75 -8.87 -4.76
Net Income / (Loss) Continuing Operations
-9.53 -9.38 -12 -11 -10 -12 -12 -9.60 -4.75 -8.87 -4.76
Total Pre-Tax Income
-9.53 -9.38 -12 -11 -10 -12 -12 -9.60 -4.75 -8.87 -4.76
Total Operating Income
-12 -12 -14 -13 -12 -14 -14 -11 -6.19 -10 -6.04
Total Gross Profit
9.94 8.94 6.24 6.41 8.89 6.99 5.23 5.69 8.08 5.60 8.47
Total Revenue
11 10 8.16 8.69 10 8.51 6.83 7.30 9.65 7.27 10
Operating Revenue
11 10 8.16 8.69 10 8.51 6.83 7.30 9.65 7.27 10
Total Cost of Revenue
1.40 1.49 1.93 2.28 1.50 1.52 1.60 1.61 1.57 1.68 1.68
Operating Cost of Revenue
1.40 1.49 1.93 2.28 1.50 1.52 1.60 1.61 1.57 1.68 1.68
Total Operating Expenses
22 21 20 19 21 21 19 17 14 16 15
Selling, General & Admin Expense
7.10 7.64 7.75 7.21 8.53 8.08 6.03 5.48 5.97 7.26 6.55
Marketing Expense
7.37 6.62 6.21 6.47 5.70 5.79 3.94 3.50 3.43 3.36 4.21
Research & Development Expense
6.68 5.62 5.32 4.61 5.90 6.27 5.32 3.34 3.86 4.25 2.87
Depreciation Expense
1.07 1.03 1.02 1.02 1.06 1.08 1.04 1.04 1.02 0.95 0.87
Restructuring Charge
- - - - - - 3.06 - - - 0.00
Total Other Income / (Expense), net
2.75 2.59 2.50 2.30 2.03 1.87 1.73 1.63 1.44 1.36 1.28
Interest & Investment Income
2.75 2.59 2.50 2.30 2.03 1.87 1.73 1.63 1.44 1.36 1.28
Income Tax Expense
- - - - - 0.00 0.00 - - 0.00 0.00
Basic Earnings per Share
($0.09) ($0.09) ($0.11) ($0.10) ($0.10) ($0.12) ($0.12) ($0.08) ($0.04) ($0.08) ($0.05)
Weighted Average Basic Shares Outstanding
104.09M 104.64M 105.11M 104.85M 105.95M 106.40M 106.61M 106.43M 106.88M 106.82M 103.54M
Diluted Earnings per Share
- ($0.09) ($0.11) - ($0.10) ($0.12) ($0.12) - ($0.04) ($0.08) ($0.05)
Weighted Average Diluted Shares Outstanding
104.09M 104.64M 105.11M 104.85M 105.95M 106.40M 106.61M 106.43M 106.88M 106.82M 103.54M
Weighted Average Basic & Diluted Shares Outstanding
104.54M 105.09M 105.48M 106.03M 106.32M 106.61M 106.67M 106.86M 107.12M 103.21M 103.25M

Annual Cash Flow Statements for MaxCyte

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
3.96 3.54 29 -37 35 -19 -7.82
Net Cash From Operating Activities
-8.80 -8.78 -11 -15 -22 -28 -34
Net Cash From Continuing Operating Activities
-8.80 -8.78 -11 -15 -22 -28 -34
Net Income / (Loss) Continuing Operations
-13 -12 -19 -24 -38 -41 -45
Consolidated Net Income / (Loss)
-13 -12 -19 -24 -38 -41 -45
Depreciation Expense
0.61 1.05 1.42 2.70 4.17 4.32 4.34
Amortization Expense
-0.03 -0.00 -0.07 -2.67 -6.73 -5.77 -1.84
Non-Cash Adjustments To Reconcile Net Income
2.37 3.46 4.95 11 17 15 14
Changes in Operating Assets and Liabilities, net
1.14 -1.47 2.10 -2.07 1.91 -0.04 -6.12
Net Cash From Investing Activities
0.45 -17 -195 -25 55 6.93 26
Net Cash From Continuing Investing Activities
0.45 -17 -195 -25 55 6.93 26
Purchase of Property, Plant & Equipment
-1.27 -2.07 -3.83 -18 -3.70 -1.65 -1.77
Acquisitions
- - - - - 0.00 -1.77
Purchase of Investments
-7.42 -23 -269 -291 -255 -151 -126
Sale and/or Maturity of Investments
9.15 8.00 78 285 314 159 156
Net Cash From Financing Activities
12 29 235 2.89 2.14 2.06 0.66
Net Cash From Continuing Financing Activities
12 29 235 2.89 2.14 2.06 0.66
Issuance of Common Equity
12 29 236 0.00 0.27 0.46 0.22
Other Financing Activities, net
0.13 0.34 3.57 2.89 1.87 1.60 0.43

Quarterly Cash Flow Statements for MaxCyte

This table details how cash moves in and out of MaxCyte's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-24 15 -0.56 -9.07 -4.50 -8.16 -2.25 7.09 -5.51 0.49 -1.67
Net Cash From Operating Activities
-11 -4.83 -4.39 -7.82 -14 -9.85 -7.46 -2.69 -8.17 -4.66 -5.51
Net Cash From Continuing Operating Activities
-11 -4.83 -4.39 -7.82 -14 -9.85 -7.46 -2.69 -8.17 -4.66 -5.51
Net Income / (Loss) Continuing Operations
-9.53 -9.38 -12 -11 -10 -12 -12 -9.60 -4.75 -8.87 -4.76
Consolidated Net Income / (Loss)
-9.53 -9.38 -12 -11 -10 -12 -12 -9.60 -4.75 -8.87 -4.76
Depreciation Expense
1.11 1.08 1.07 1.06 1.10 1.10 1.07 1.07 1.05 0.98 0.90
Amortization Expense
-1.87 -1.68 -1.39 -0.72 -0.70 -0.55 -0.38 -0.21 -0.22 -0.17 -0.18
Non-Cash Adjustments To Reconcile Net Income
3.16 3.82 4.52 4.15 3.15 3.15 2.02 5.52 1.35 2.08 0.99
Changes in Operating Assets and Liabilities, net
-3.44 1.33 2.97 -1.71 -7.69 -1.19 2.24 0.52 -5.60 1.33 -2.45
Net Cash From Investing Activities
-14 19 3.61 -1.67 9.53 1.54 5.19 9.68 2.66 6.57 7.86
Net Cash From Continuing Investing Activities
-14 19 3.61 -1.67 9.53 1.54 5.19 9.68 2.66 6.57 7.86
Purchase of Property, Plant & Equipment
-0.80 -0.29 -0.41 -0.15 -0.65 -0.58 -0.30 -0.23 -0.07 -0.06 -0.06
Purchase of Investments
-48 -31 -39 -33 -35 -29 -35 -28 -25 -11 -19
Sale and/or Maturity of Investments
34 51 43 31 47 31 40 38 28 18 27
Net Cash From Financing Activities
0.70 0.71 0.23 0.41 0.38 0.15 0.01 0.11 0.01 -1.42 -4.02
Net Cash From Continuing Financing Activities
0.70 0.71 0.23 0.41 0.38 0.15 0.01 0.11 0.01 -1.42 -4.02
Repurchase of Common Equity
- - - - - - - - - - -4.02

Annual Balance Sheets for MaxCyte

This table presents MaxCyte's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
52 284 287 268 239 203
Total Current Assets
45 270 252 190 172 118
Cash & Equivalents
19 48 11 47 28 20
Short-Term Investments
16 207 216 122 127 83
Accounts Receivable
5.17 6.88 13 5.78 4.68 3.50
Inventories, net
4.32 5.20 8.58 12 8.91 7.55
Prepaid Expenses
1.00 3.31 3.26 3.90 3.61 4.28
Other Current Assets
- - - - - 0.00
Plant, Property, & Equipment, net
4.55 7.68 24 24 20 18
Total Noncurrent Assets
1.98 6.01 11 55 48 67
Long-Term Investments
- - 0.00 43 36 53
Intangible Assets
- - - - 0.00 0.65
Other Noncurrent Operating Assets
1.76 6.01 11 12 12 13
Total Liabilities & Shareholders' Equity
52 284 287 268 239 203
Total Liabilities
19 21 33 36 33 31
Total Current Liabilities
12 16 15 18 16 14
Accounts Payable
0.89 1.82 0.29 0.74 1.36 1.40
Accrued Expenses
5.31 6.52 8.27 11 8.30 7.81
Current Deferred Revenue
4.84 6.75 6.71 5.07 5.25 3.60
Other Current Liabilities
0.57 0.53 0.16 0.77 0.86 1.46
Total Noncurrent Liabilities
6.94 5.61 17 18 17 17
Other Noncurrent Operating Liabilities
2.02 5.61 17 18 17 17
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
33 263 254 232 206 171
Total Preferred & Common Equity
33 263 254 232 206 171
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
33 263 254 232 206 171
Common Stock
128 377 392 408 423 433
Retained Earnings
-95 -114 -138 -176 -217 -261
Treasury Stock
- - - - - 0.00

Quarterly Balance Sheets for MaxCyte

This table presents MaxCyte's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
271 267 258 251 249 230 220 213 194 185 182
Total Current Assets
237 214 179 176 173 156 143 125 123 121 125
Cash & Equivalents
55 49 22 38 37 23 15 13 15 15 13
Short-Term Investments
162 141 135 120 117 115 111 93 92 91 88
Accounts Receivable
7.61 8.17 5.99 4.58 4.56 5.53 5.75 8.31 4.25 3.92 12
Inventories, net
11 13 12 11 10 8.27 7.93 7.61 7.63 7.80 7.38
Prepaid Expenses
1.88 3.40 3.21 2.58 4.12 3.68 2.97 3.00 4.21 3.66 3.78
Other Current Assets
- - - - - - - - - 0.20 0.18
Plant, Property, & Equipment, net
24 24 23 22 21 20 19 19 17 15 14
Total Noncurrent Assets
10 29 56 54 55 54 57 70 55 49 43
Long-Term Investments
- 18 45 42 43 36 39 52 41 36 31
Intangible Assets
- - - - - 0.50 0.64 0.67 0.78 0.77 0.75
Other Noncurrent Operating Assets
10 10 11 12 12 13 14 14 13 12 11
Total Liabilities & Shareholders' Equity
271 267 258 251 249 230 220 213 194 185 182
Total Liabilities
30 33 32 30 35 31 29 33 27 26 32
Total Current Liabilities
13 17 13 12 18 13 12 16 10 9.90 16
Accounts Payable
1.60 0.45 1.67 0.95 1.87 2.28 1.21 1.29 1.20 1.73 1.03
Accrued Expenses
6.41 9.92 6.50 7.08 8.20 5.03 6.40 8.31 4.37 4.17 5.94
Current Deferred Revenue
4.69 5.59 4.48 3.37 6.65 4.15 2.64 5.20 3.27 2.46 7.39
Other Current Liabilities
0.50 0.70 0.83 0.88 0.91 1.28 1.31 1.31 1.37 1.53 1.57
Total Noncurrent Liabilities
17 17 18 18 18 18 17 17 16 16 16
Other Noncurrent Operating Liabilities
17 17 18 18 18 18 17 17 16 16 16
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
241 233 226 221 213 199 191 180 168 159 151
Total Preferred & Common Equity
241 233 226 221 213 199 191 180 168 159 151
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
241 233 226 221 213 199 191 180 168 159 151
Common Stock
400 404 412 416 420 427 430 432 434 435 436
Retained Earnings
-159 -171 -185 -195 -206 -227 -239 -252 -266 -275 -280
Treasury Stock
- - - - - - - - - -1.48 -5.50

Annual Metrics And Ratios for MaxCyte

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 0.00 100,434,032.00 - - - 106,674,011.00
DEI Adjusted Shares Outstanding
0.00 0.00 100,434,032.00 - - - 106,674,011.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 0.00 -0.19 - - - -0.42
Growth Metrics
- - - - - - -
Revenue Growth
0.00% 21.04% 29.52% 30.59% -6.72% -6.45% -14.50%
EBITDA Growth
0.00% 15.43% -68.13% -62.34% -86.07% -3.53% 6.17%
EBIT Growth
0.00% 10.98% -64.50% -50.43% -76.53% -6.00% -1.37%
NOPAT Growth
0.00% 10.98% -64.50% -50.43% -76.53% -6.00% -1.37%
Net Income Growth
0.00% 8.36% -61.49% -23.52% -60.89% -8.26% -8.71%
EPS Growth
0.00% 26.09% -23.53% -9.52% -60.87% -5.41% -7.69%
Operating Cash Flow Growth
0.00% 0.23% -21.61% -38.42% -46.70% -27.32% -24.63%
Free Cash Flow Firm Growth
0.00% 0.00% -54.74% -120.44% 25.85% -9.82% -17.26%
Invested Capital Growth
0.00% 0.00% 132.37% 239.07% -21.36% -23.65% -0.70%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 5.41% 8.52% -15.29% -4.04%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% -11.28% -2.53% -7.27% 4.90%
EBIT Q/Q Growth
0.00% 0.00% 0.00% -7.02% -2.86% -10.36% 3.13%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% -7.02% -2.86% -10.36% 3.13%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 0.27% -1.25% -14.88% 2.19%
EPS Q/Q Growth
0.00% 0.00% 0.00% -4.55% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 8.18% -53.08% 24.58% -46.80% 12.98%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 21.94% -26.37% 15.97%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 23.58% -15.24% -4.11% -28.72%
Profitability Metrics
- - - - - - -
Gross Margin
88.44% 89.43% 89.24% 88.48% 88.51% 81.62% 81.16%
EBITDA Margin
-54.76% -38.26% -49.67% -61.75% -123.17% -136.30% -149.58%
Operating Margin
-57.44% -42.25% -53.66% -61.82% -116.98% -132.54% -157.14%
EBIT Margin
-57.44% -42.25% -53.66% -61.82% -116.98% -132.54% -157.14%
Profit (Net Income) Margin
-59.64% -45.15% -56.30% -53.25% -91.85% -106.29% -135.14%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
103.82% 106.87% 104.91% 86.15% 78.52% 80.19% 86.00%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% -458.01% -226.69% -111.09% -142.15% -194.09% -228.02%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% -430.69% -222.23% -109.26% -140.27% -191.49% -223.22%
Return on Net Nonoperating Assets (RNNOA)
0.00% 386.88% 213.80% 101.97% 126.55% 175.36% 204.39%
Return on Equity (ROE)
0.00% -71.13% -12.89% -9.12% -15.60% -18.73% -23.63%
Cash Return on Invested Capital (CROIC)
0.00% -658.01% -306.34% -219.99% -118.24% -167.27% -227.32%
Operating Return on Assets (OROA)
0.00% -21.35% -10.83% -9.59% -17.41% -20.17% -23.48%
Return on Assets (ROA)
0.00% -22.82% -11.36% -8.26% -13.67% -16.17% -20.20%
Return on Common Equity (ROCE)
0.00% -71.13% -12.89% -9.12% -15.60% -18.73% -23.63%
Return on Equity Simple (ROE_SIMPLE)
0.00% -35.56% -7.26% -9.28% -16.33% -19.91% 0.00%
Net Operating Profit after Tax (NOPAT)
-8.69 -7.74 -13 -19 -34 -36 -36
NOPAT Margin
-40.21% -29.58% -37.56% -43.27% -81.89% -92.78% -110.00%
Net Nonoperating Expense Percent (NNEP)
0.00% -27.32% -4.46% -1.83% -1.88% -2.60% -4.80%
Return On Investment Capital (ROIC_SIMPLE)
- - - - -14.56% -17.38% -21.18%
Cost of Revenue to Revenue
11.56% 10.57% 10.76% 11.52% 11.49% 18.38% 18.84%
SG&A Expenses to Revenue
25.70% 28.16% 55.10% 58.36% 72.83% 76.87% 85.13%
R&D to Revenue
81.37% 67.77% 45.46% 44.09% 57.69% 57.54% 63.05%
Operating Expenses to Revenue
145.89% 131.68% 142.90% 150.30% 205.50% 214.16% 238.30%
Earnings before Interest and Taxes (EBIT)
-12 -11 -18 -27 -48 -51 -52
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-12 -10 -17 -27 -51 -53 -49
Valuation Ratios
- - - - - - -
Price to Book Value (P/BV)
0.00 0.59 3.89 2.19 2.10 2.13 0.96
Price to Tangible Book Value (P/TBV)
0.00 0.59 3.89 2.19 2.10 2.13 0.97
Price to Revenue (P/Rev)
0.90 0.75 30.19 12.59 11.79 11.36 5.01
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 97.84 12.39 13.16 15.55 0.61
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 22.67 7.45 6.67 6.43 0.29
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - -
Debt to Equity
0.00 0.15 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.15 0.00 0.00 0.00 0.00 0.00
Financial Leverage
0.00 -0.90 -0.96 -0.93 -0.90 -0.92 -0.92
Leverage Ratio
0.00 1.56 1.13 1.10 1.14 1.16 1.17
Compound Leverage Factor
0.00 1.67 1.19 0.95 0.90 0.93 1.01
Debt to Total Capital
0.00% 12.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 12.89% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 87.11% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 -0.49 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 2.98 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 -0.49 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 -0.64 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 3.86 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 -0.64 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
0.00 -1.36 29.35 10.39 7.50 6.90 1.33
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - -
Current Ratio
0.00 3.90 17.32 16.35 10.65 10.88 8.30
Quick Ratio
0.00 3.44 16.77 15.58 9.75 10.09 7.47
Cash Flow Metrics
- - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -11 -17 -38 -28 -31 -36
Operating Cash Flow to CapEx
-692.40% -423.83% -278.87% -80.01% -587.54% -1,672.32% -1,946.27%
Free Cash Flow to Firm to Interest Expense
0.00 -13.47 -16.47 -298.64 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-12.92 -10.64 -10.23 -116.40 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-14.79 -13.15 -13.89 -261.89 0.00 0.00 0.00
Efficiency Ratios
- - - - - - -
Asset Turnover
0.00 0.51 0.20 0.16 0.15 0.15 0.15
Accounts Receivable Turnover
0.00 5.06 5.63 4.43 4.38 7.39 8.07
Inventory Turnover
0.00 0.64 0.77 0.74 0.46 0.67 0.76
Fixed Asset Turnover
0.00 5.76 5.54 2.82 1.75 1.79 1.77
Accounts Payable Turnover
0.00 3.11 2.69 4.83 9.16 6.76 4.51
Days Sales Outstanding (DSO)
0.00 72.14 64.88 82.32 83.39 49.42 45.23
Days Inventory Outstanding (DIO)
0.00 569.31 476.36 493.50 800.89 543.46 482.82
Days Payable Outstanding (DPO)
0.00 117.43 135.62 75.62 39.83 54.00 80.93
Cash Conversion Cycle (CCC)
0.00 524.01 405.61 500.20 844.44 538.88 447.13
Capital & Investment Metrics
- - - - - - -
Invested Capital
0.00 3.38 7.85 27 21 16 16
Invested Capital Turnover
0.00 15.49 6.03 2.57 1.74 2.09 2.07
Increase / (Decrease) in Invested Capital
0.00 3.38 4.47 19 -5.69 -4.95 -0.11
Enterprise Value (EV)
0.00 -10 768 330 276 249 9.73
Market Capitalization
20 20 1,023 557 487 439 165
Book Value per Share
$0.00 $0.48 $2.62 $2.49 $2.24 $1.96 $1.61
Tangible Book Value per Share
$0.00 $0.48 $2.62 $2.49 $2.24 $1.96 $1.60
Total Capital
0.00 38 263 254 232 206 171
Total Debt
0.00 4.92 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 4.92 0.00 0.00 0.00 0.00 0.00
Net Debt
0.00 -30 -255 -227 -211 -190 -156
Capital Expenditures (CapEx)
1.27 2.07 3.83 18 3.69 1.65 1.77
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -1.12 -0.23 9.50 4.05 1.43 1.06
Debt-free Net Working Capital (DFNWC)
0.00 34 255 237 172 156 104
Net Working Capital (NWC)
0.00 34 255 237 172 156 104
Net Nonoperating Expense (NNE)
4.20 4.08 6.35 4.42 4.11 5.22 8.30
Net Nonoperating Obligations (NNO)
0.00 -30 -255 -227 -211 -190 -156
Total Depreciation and Amortization (D&A)
0.58 1.04 1.35 0.03 -2.55 -1.45 2.50
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -4.29% -0.68% 21.46% 9.81% 3.69% 3.20%
Debt-free Net Working Capital to Revenue
0.00% 128.55% 751.80% 535.10% 417.41% 403.63% 315.21%
Net Working Capital to Revenue
0.00% 128.55% 751.80% 535.10% 417.41% 403.63% 315.21%
Earnings Adjustments
- - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 ($0.21) ($0.23) ($0.37) ($0.39) ($0.42)
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 90.62M 101.70M 103.27M 104.85M 106.43M
Adjusted Diluted Earnings per Share
$0.00 $0.00 ($0.21) ($0.23) ($0.37) ($0.39) ($0.42)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 90.62M 101.70M 103.27M 104.85M 106.43M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 101.51M 102.90M 104.13M 106.03M 106.86M
Normalized Net Operating Profit after Tax (NOPAT)
-8.69 -7.74 -13 -19 -34 -36 -34
Normalized NOPAT Margin
-40.21% -29.58% -37.56% -43.27% -81.89% -92.78% -102.47%
Pre Tax Income Margin
-59.64% -45.15% -56.30% -53.25% -91.85% -106.29% -135.14%
Debt Service Ratios
- - - - - - -
EBIT to Interest Expense
-18.24 -13.39 -17.42 -215.44 0.00 0.00 0.00
NOPAT to Interest Expense
-12.76 -9.37 -12.19 -150.81 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-20.10 -15.90 -21.08 -360.93 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-14.63 -11.88 -15.86 -296.30 0.00 0.00 0.00
Payout Ratios
- - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for MaxCyte

This table displays calculated financial ratios and metrics derived from MaxCyte's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - 106,027,733.00 106,318,532.00 106,606,648.00 106,674,011.00 106,861,428.00 107,121,672.00 103,206,206.00
DEI Adjusted Shares Outstanding
- - - - 106,027,733.00 106,318,532.00 106,606,648.00 106,674,011.00 106,861,428.00 107,121,672.00 103,206,206.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - -0.10 -0.12 -0.12 -0.09 -0.04 -0.08 -0.05
Growth Metrics
- - - - - - - - - - -
Revenue Growth
32.25% 15.33% 2.00% -44.51% -8.39% -18.43% -16.35% -16.01% -7.11% -14.53% 48.66%
EBITDA Growth
5.73% 9.95% -0.15% -46.10% 8.66% -7.85% 4.06% 19.72% 55.02% 31.09% 60.46%
EBIT Growth
6.85% 8.45% -0.72% -59.35% -0.16% -18.88% -0.68% 12.98% 49.70% 28.08% 57.30%
NOPAT Growth
6.85% 8.45% -0.72% -59.35% -0.16% -18.88% -0.68% 12.98% 49.70% 28.08% 57.30%
Net Income Growth
12.46% 10.82% -2.72% -100.78% -7.72% -31.81% -7.43% 9.45% 53.71% 28.19% 61.65%
EPS Growth
0.00% 10.00% 0.00% 0.00% 0.00% -33.33% -9.09% 0.00% 60.00% 33.33% 58.33%
Operating Cash Flow Growth
-144.31% 52.16% 46.70% -897.25% -36.42% -103.81% -69.85% 65.62% 43.31% 52.69% 26.17%
Free Cash Flow Firm Growth
50.32% 72.73% 86.06% -20,694.44% -2.91% -184.02% -760.06% -89.96% 101.77% 111.16% 99.11%
Invested Capital Growth
2.80% -13.76% -32.52% -23.65% 3.80% 19.17% 33.59% -0.70% -18.20% -34.16% -18.37%
Revenue Q/Q Growth
-27.59% -8.05% -21.72% 6.47% 19.54% -18.12% -19.72% 6.90% 32.21% -24.66% 39.62%
EBITDA Q/Q Growth
-46.24% 4.40% -14.36% 12.63% 7.82% -14.95% 1.67% 22.94% 48.35% -76.09% 43.58%
EBIT Q/Q Growth
-51.63% 2.50% -17.42% 8.20% 4.70% -15.71% 0.55% 20.66% 44.90% -65.43% 40.96%
NOPAT Q/Q Growth
-51.63% 2.50% -17.42% 8.20% 4.70% -15.71% 0.55% 20.66% 44.90% -65.43% 40.96%
Net Income Q/Q Growth
-80.51% 1.59% -23.27% 8.31% 3.17% -20.43% -0.48% 22.71% 50.50% -86.82% 46.34%
EPS Q/Q Growth
0.00% 0.00% -22.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 37.50%
Operating Cash Flow Q/Q Growth
-1,176.09% 54.24% 9.16% -78.11% -84.26% 31.64% 24.30% 63.94% -203.79% 42.94% -18.13%
Free Cash Flow Firm Q/Q Growth
-45,646.57% 46.40% 63.61% -126.20% -133.23% -47.94% -10.19% 50.04% 102.18% 831.51% -108.77%
Invested Capital Q/Q Growth
13.72% -9.93% -22.27% -4.11% 54.61% 3.41% -12.86% -28.72% 27.37% -16.77% 8.04%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
87.63% 85.73% 76.38% 73.76% 85.59% 82.14% 76.63% 77.95% 83.74% 76.96% 83.41%
EBITDA Margin
-115.91% -120.52% -176.07% -144.49% -114.55% -160.82% -196.98% -142.00% -55.48% -129.67% -52.39%
Operating Margin
-108.23% -114.76% -172.13% -148.42% -118.33% -167.24% -207.19% -153.78% -64.09% -140.72% -59.51%
EBIT Margin
-108.23% -114.76% -172.13% -148.42% -118.33% -167.24% -207.19% -153.78% -64.09% -140.72% -59.51%
Profit (Net Income) Margin
-83.99% -89.89% -141.56% -121.92% -98.76% -145.26% -181.81% -131.45% -49.22% -122.05% -46.91%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
77.60% 78.33% 82.24% 82.14% 83.46% 86.86% 87.75% 85.48% 76.80% 86.73% 78.83%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-142.08% -157.59% -265.56% -217.35% -128.60% -178.06% -256.34% -223.14% -64.46% -144.31% -70.79%
ROIC Less NNEP Spread (ROIC-NNEP)
-141.64% -157.11% -264.71% -216.57% -127.73% -176.75% -254.93% -222.14% -64.20% -143.20% -70.42%
Return on Net Nonoperating Assets (RNNOA)
127.61% 141.37% 240.19% 198.33% 113.17% 156.58% 229.70% 203.40% 56.34% 125.83% 61.82%
Return on Equity (ROE)
-14.47% -16.22% -25.37% -19.02% -15.44% -21.48% -26.64% -19.74% -8.12% -18.48% -8.97%
Cash Return on Invested Capital (CROIC)
-144.00% -125.12% -118.12% -167.27% -151.46% -176.74% -221.33% -227.32% -122.62% -96.83% -96.34%
Operating Return on Assets (OROA)
-17.68% -19.95% -30.46% -22.58% -18.28% -25.38% -30.86% -22.98% -9.75% -21.61% -10.33%
Return on Assets (ROA)
-13.72% -15.63% -25.05% -18.55% -15.25% -22.04% -27.08% -19.65% -7.49% -18.74% -8.14%
Return on Common Equity (ROCE)
-14.47% -16.22% -25.37% -19.02% -15.44% -21.48% -26.64% -19.74% -8.12% -18.48% -8.97%
Return on Equity Simple (ROE_SIMPLE)
-16.15% -16.01% -16.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-8.59 -8.38 -9.84 -9.03 -8.61 -9.96 -9.90 -7.86 -4.33 -7.16 -4.23
NOPAT Margin
-75.76% -80.33% -120.49% -103.90% -82.83% -117.07% -145.03% -107.65% -44.86% -98.51% -41.65%
Net Nonoperating Expense Percent (NNEP)
-0.44% -0.48% -0.85% -0.78% -0.88% -1.31% -1.42% -1.00% -0.26% -1.11% -0.37%
Return On Investment Capital (ROIC_SIMPLE)
- - - -4.38% -4.32% -5.22% -5.49% -4.58% -2.58% -4.51% -2.80%
Cost of Revenue to Revenue
12.37% 14.27% 23.62% 26.24% 14.41% 17.86% 23.37% 22.05% 16.26% 23.04% 16.59%
SG&A Expenses to Revenue
62.63% 73.25% 94.87% 82.90% 82.06% 94.98% 88.27% 75.10% 61.82% 99.82% 64.55%
R&D to Revenue
58.88% 53.88% 65.12% 53.08% 56.81% 73.69% 77.84% 45.68% 39.96% 58.49% 28.31%
Operating Expenses to Revenue
195.86% 200.49% 248.52% 222.18% 203.93% 249.38% 283.82% 231.73% 147.83% 217.69% 142.92%
Earnings before Interest and Taxes (EBIT)
-12 -12 -14 -13 -12 -14 -14 -11 -6.19 -10 -6.04
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -13 -14 -13 -12 -14 -13 -10 -5.35 -9.43 -5.32
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.93 1.85 1.92 2.13 1.45 1.22 0.93 0.96 0.45 0.83 0.77
Price to Tangible Book Value (P/TBV)
1.93 1.85 1.92 2.13 1.48 1.24 0.96 0.97 0.45 0.83 0.77
Price to Revenue (P/Rev)
9.90 9.02 8.96 11.36 7.68 6.48 4.89 5.01 2.33 4.24 3.36
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
9.82 9.79 12.73 15.55 4.64 2.61 0.47 0.61 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
5.31 4.62 4.65 6.43 3.05 1.86 0.30 0.29 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.90 -0.90 -0.91 -0.92 -0.89 -0.89 -0.90 -0.92 -0.88 -0.88 -0.88
Leverage Ratio
1.14 1.13 1.15 1.16 1.15 1.14 1.17 1.17 1.16 1.16 1.20
Compound Leverage Factor
0.88 0.89 0.95 0.95 0.96 0.99 1.03 1.00 0.89 1.00 0.94
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
8.07 7.85 6.53 7.42 5.04 3.93 1.94 1.99 0.53 1.67 0.85
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
13.26 14.31 9.81 10.88 12.23 12.39 7.74 8.30 12.04 12.26 7.83
Quick Ratio
12.13 13.19 8.99 10.09 11.29 11.45 7.08 7.47 10.88 11.08 7.12
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-9.24 -4.95 -1.80 -4.08 -9.51 -14 -16 -7.75 0.17 1.57 -0.14
Operating Cash Flow to CapEx
-1,313.93% -1,644.22% -1,081.53% -5,320.41% -2,206.89% -1,686.99% -2,486.00% -1,164.07% -11,345.83% -7,517.74% -9,332.20%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.16 0.17 0.18 0.15 0.15 0.15 0.15 0.15 0.15 0.15 0.17
Accounts Receivable Turnover
5.77 7.46 7.17 7.39 6.54 6.92 5.35 8.07 6.61 6.42 3.38
Inventory Turnover
0.46 0.47 0.56 0.67 0.71 0.76 0.77 0.76 0.79 0.82 0.87
Fixed Asset Turnover
1.85 1.97 2.04 1.79 1.76 1.74 1.74 1.77 1.77 1.81 2.09
Accounts Payable Turnover
1.99 4.11 5.53 6.76 3.64 6.68 4.38 4.51 3.62 4.38 5.66
Days Sales Outstanding (DSO)
63.31 48.95 50.93 49.42 55.78 52.75 68.22 45.23 55.23 56.86 108.10
Days Inventory Outstanding (DIO)
788.35 769.97 654.56 543.46 513.30 482.25 476.68 482.82 461.18 445.10 418.45
Days Payable Outstanding (DPO)
183.60 88.73 66.00 54.00 100.28 54.64 83.43 80.93 100.76 83.30 64.54
Cash Conversion Cycle (CCC)
668.05 730.20 639.50 538.88 468.81 480.37 461.47 447.13 415.65 418.67 462.01
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
24 21 17 16 25 26 22 16 20 17 18
Invested Capital Turnover
1.88 1.96 2.20 2.09 1.55 1.52 1.77 2.07 1.44 1.47 1.70
Increase / (Decrease) in Invested Capital
0.65 -3.42 -8.03 -4.95 0.90 4.11 5.60 -0.11 -4.50 -8.73 -4.09
Enterprise Value (EV)
234 210 212 249 115 67 10 9.73 -73 -10 -17
Market Capitalization
436 410 409 439 289 232 168 165 75 132 116
Book Value per Share
$2.17 $2.12 $2.03 $1.96 $1.88 $1.79 $1.69 $1.61 $1.57 $1.48 $1.46
Tangible Book Value per Share
$2.17 $2.12 $2.03 $1.96 $1.84 $1.75 $1.65 $1.60 $1.56 $1.47 $1.46
Total Capital
226 221 213 206 199 191 180 171 168 159 151
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-203 -200 -197 -190 -175 -165 -158 -156 -148 -142 -133
Capital Expenditures (CapEx)
0.80 0.29 0.41 0.15 0.65 0.58 0.30 0.23 0.07 0.06 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)
7.68 6.04 1.46 1.43 4.75 5.10 2.82 1.06 5.87 5.69 7.48
Debt-free Net Working Capital (DFNWC)
165 163 155 156 143 132 109 104 113 111 109
Net Working Capital (NWC)
165 163 155 156 143 132 109 104 113 111 109
Net Nonoperating Expense (NNE)
0.93 1.00 1.72 1.57 1.65 2.40 2.51 1.74 0.42 1.71 0.53
Net Nonoperating Obligations (NNO)
-203 -200 -197 -190 -175 -165 -158 -156 -148 -142 -133
Total Depreciation and Amortization (D&A)
-0.87 -0.60 -0.32 0.34 0.39 0.55 0.70 0.86 0.83 0.80 0.72
Debt-free, Cash-free Net Working Capital to Revenue
17.44% 13.30% 3.19% 3.69% 12.59% 14.27% 8.18% 3.20% 18.18% 18.32% 21.75%
Debt-free Net Working Capital to Revenue
374.99% 359.53% 340.54% 403.63% 379.60% 368.26% 315.37% 315.21% 349.13% 358.70% 316.39%
Net Working Capital to Revenue
374.99% 359.53% 340.54% 403.63% 379.60% 368.26% 315.37% 315.21% 349.13% 358.70% 316.39%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.09) ($0.09) ($0.11) ($0.10) ($0.10) ($0.12) ($0.12) ($0.08) ($0.04) ($0.08) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding
104.09M 104.64M 105.11M 104.85M 105.95M 106.40M 106.61M 106.43M 106.88M 106.82M 103.54M
Adjusted Diluted Earnings per Share
$0.00 ($0.09) ($0.11) $0.00 $0.00 ($0.12) ($0.12) $0.00 ($0.04) ($0.08) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding
104.54M 104.64M 105.11M 104.85M 105.95M 106.40M 106.61M 106.43M 106.88M 106.82M 103.54M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
104.54M 105.09M 105.48M 106.03M 106.32M 106.61M 106.67M 106.86M 107.12M 103.21M 103.25M
Normalized Net Operating Profit after Tax (NOPAT)
-8.59 -8.38 -9.84 -9.03 -8.61 -9.96 -9.90 -7.86 -4.33 -7.16 -4.23
Normalized NOPAT Margin
-75.76% -80.33% -120.49% -103.90% -82.83% -117.07% -145.03% -107.65% -44.86% -98.51% -41.65%
Pre Tax Income Margin
-83.99% -89.89% -141.56% -121.92% -98.76% -145.26% -181.81% -131.45% -49.22% -122.05% -46.91%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

MaxCyte’s latest financial statements show improving cost control and a strong balance sheet, but revenue growth remains the central challenge. Q2 2026 revenue was $7.3 million, down from $8.5 million in Q2 2025 and $10.4 million in Q2 2024. Revenue has generally remained below the $10 million-plus quarterly levels reported in 2023 and early 2024.

Profitability improved sequentially and year over year. The Q2 2026 operating loss narrowed to $10.2 million from $14.2 million in Q2 2025, while the net loss improved to $8.9 million from $12.4 million. The improvement was primarily driven by lower selling, general and administrative costs and lower research and development spending. However, MaxCyte remained unprofitable, with diluted EPS of negative $0.08.

Cash usage also improved. Operating cash flow was negative $4.7 million in Q2 2026, compared with negative $8.2 million in Q1 2026 and negative $9.9 million in Q2 2025. Even so, operating cash flow remained negative, and the company relied partly on investment maturities and sales to produce positive quarterly changes in cash.

  • Strong liquidity and limited balance-sheet leverage: MaxCyte held $15.0 million in cash, $90.6 million in short-term investments and $36.2 million in long-term investments at June 30, 2026. Total liabilities were only $25.9 million, providing a substantial liquidity cushion relative to current operating losses.
  • Operating losses are narrowing: The Q2 2026 operating loss of $10.2 million improved from $14.1 million in Q3 2025 and $14.2 million in Q2 2025. Total operating expenses also fell to $15.8 million from $21.2 million in Q2 2025.
  • Lower cash burn: Negative operating cash flow of $4.7 million in Q2 2026 was the company’s best result among the latest four reported quarters, suggesting that working-capital management and expense reductions are beginning to help.
  • Healthy working-capital position: Current assets of $121.3 million compared with current liabilities of $9.9 million imply substantial short-term coverage, even though current assets have declined from earlier periods.
  • Investment income remains a partial offset: Interest and investment income contributed $1.4 million in Q2 2026. This provides some support, but it represents only a small portion of the company’s operating losses and has declined from approximately $2.6 million in Q2 2024.
  • Investment transactions are driving cash-flow volatility: MaxCyte purchased $11.4 million of investments and received $18.0 million from investment sales or maturities in Q2 2026. Positive investing cash flow therefore reflects portfolio management rather than internally generated operating cash.
  • Revenue continues to trend lower: Q2 2026 revenue of $7.3 million was approximately 15% below Q2 2025 and roughly 30% below Q2 2024. The decline indicates that expense reductions have not yet been matched by a sustained recovery in demand or commercial activity.
  • Gross margin weakened: Gross profit was $5.6 million in Q2 2026, representing a margin of about 77%, compared with approximately 82% in Q2 2025 and 86% in Q2 2024. Lower revenue and margin compression make a return to profitability more difficult.
  • Recurring losses continue to reduce retained earnings: Retained earnings fell to negative $275.1 million at June 30, 2026, compared with negative $239.5 million at June 30, 2025. Continued losses will gradually reduce shareholder equity and liquidity if the company does not achieve positive cash flow.
  • MaxCyte remains dependent on its cash reserves: Operating cash flow was negative in each of the latest reported quarters, and cumulative operating cash flow for the first half of 2026 was approximately negative $12.8 million. Without a meaningful improvement in revenue and margins, the company may eventually need to reduce spending further or raise capital.

Overall, MaxCyte’s financial risk is moderated by its investment portfolio, low liabilities and improving expense discipline. Nevertheless, the multi-year decline in revenue, persistent operating losses and continued cash burn suggest that investors will likely focus on whether the company can stabilize sales and convert its cost reductions into sustainable profitability.

11/17/26 02:51 PM ETAI Generated. May Contain Errors.

MaxCyte Financials - Frequently Asked Questions

According to the most recent income statement we have on file, MaxCyte's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

MaxCyte's net income appears to be on a downward trend, with a most recent value of -$44.63 million in 2025, falling from -$12.90 million in 2019. The previous period was -$41.06 million in 2024. View MaxCyte's forecast to see where analysts expect MaxCyte to go next.

MaxCyte's total operating income in 2025 was -$51.90 million, based on the following breakdown:
  • Total Gross Profit: $26.80 million
  • Total Operating Expenses: $78.70 million

Over the last 6 years, MaxCyte's total revenue changed from $21.62 million in 2019 to $33.03 million in 2025, a change of 52.8%.

In the past 13 quarters, MaxCyte's cash and equivalents has ranged from $12.97 million in Q3 2025 to $54.56 million in Q2 2023, and is currently $13.37 million as of their latest financial filing in Q3 2026.

MaxCyte had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2019.

Over the last 6 years, MaxCyte's book value per share changed from 0.00 in 2019 to 1.61 in 2025, a change of 160.8%.



Financial statements for NASDAQ:MXCT last updated on 11/10/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners